Results 201 to 210 of about 3,729,717 (272)
Some of the next articles are maybe not open access.
The human NTG model of migraine in drug discovery and development
Expert Opinion on Drug Discovery, 2023Introduction Various triggers can originate a migraine attack. In healthy volunteers and patients with migraine, the nitroglycerin (NTG) provocation model induces a headache that resembles migraine in pain characteristics and vascular manifestations ...
Lanfranco Pellesi
semanticscholar +1 more source
Transdermal nitroglycerin as a step 3 antihypertensive drug
Clinical Pharmacology and Therapeutics, 1986The antihypertensive effect of transdermal nitroglycerin was tested in 11 men with hypertension (mean age 60 years) whose diastolic blood pressure exceeded 90 mm Hg while receiving a diuretic and a beta-adrenergic blocker. In a double-blind, randomized crossover trial the subjects received weekly increments of placebo or nitroglycerin (5, 10, 20, and ...
G. Simon, Virginia J. Wittig, J. Cohn
semanticscholar +4 more sources
Transdermal Absorption of Nitroglycerin from Microseal Drug Delivery (MDD) System
Angiology, 1983A recent important advance in biopharmaceutics has been the utilization of controlled delivery of drugs to the systemic circulation through the intact skin. With the conventional tablet and capsule dosage forms, the amount of drug absorbed through the gastrointestinal (GI) tract varies depending on the quan tity and types of food in the stomach, on ...
A. Karim
semanticscholar +4 more sources
Journal of Physical Chemistry B, 2021
Nitric oxide-containing drugs present a critical remedy for cardiovascular diseases. Nitroglycerin (NG, O-NO) and S-nitrosoglutathione (SNG, S-NO) are the most common nitric oxide drugs for cardiovascular diseases. Insights regarding the binding affinity
C. Nassab +5 more
semanticscholar +1 more source
Nitric oxide-containing drugs present a critical remedy for cardiovascular diseases. Nitroglycerin (NG, O-NO) and S-nitrosoglutathione (SNG, S-NO) are the most common nitric oxide drugs for cardiovascular diseases. Insights regarding the binding affinity
C. Nassab +5 more
semanticscholar +1 more source
BIOEQUIVALENCE COMPARISON OF TWO DRUG‐IN-ADHESIVE TRANSDERMAL NITROGLYCERIN PATCHES
American Journal of Therapeutics, 1996Plasma concentrations of nitroglycerin, 1,2-dinitroglycerin and 1,3-dinitroglycerin in 50 healthy male subjects who received single 24-h applications of two 0.6 mg/h drug-in-adhesive transdermal nitroglycerin patch formulations were compared for the purpose of establishing bioequivalence.
L. Harrison +7 more
semanticscholar +3 more sources
Transdermal nitroglycerin prevents nonsteroidal anti-inflammatory drug gastropathy.
European Journal of Pharmacology, 1995Abstract The application of a transdermal nitroglycerin patch (2–30 μg/3 h/rat) protected, in a dose-dependent manner, the rat gastric mucosa against damage induced by the nonsteroidal anti-inflammatory agent indomethacin (20 mg/kg s.c.).
M. Barrachina +6 more
semanticscholar +4 more sources
Journal of Chromatographic Science, 2019
A large number of laboratory studies have reported Nitrite (NO2-) and Nitrate (NO3-) to be among the most common degradation products of the high-explosive Nitroglycerin drug substance.
Pritesh Desai, P. Mehta, Avani Chokshi
semanticscholar +1 more source
A large number of laboratory studies have reported Nitrite (NO2-) and Nitrate (NO3-) to be among the most common degradation products of the high-explosive Nitroglycerin drug substance.
Pritesh Desai, P. Mehta, Avani Chokshi
semanticscholar +1 more source
Assessment of the Drug Interaction Between Alteplase and Nitroglycerin: An In Vitro Study
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2000 Alteplase is the most commonly administered thrombolytic agent in the United States. However, concurrent therapy with nitroglycerin reduces plasma alteplase concentrations and its clinical efficacy. We sought to determine if this interaction is concentration and pH dependent. Seventy plasma samples were prepared and divided into three groups: alteplase
C Michael White +4 more
openalex +4 more sources
Antianginal drugs. Part II. Human pharmacology of nitroglycerin
American Heart Journal, 1966 Solomon Fisch
openalex +4 more sources
Antianginal drugs. Part III. Clinical use of nitroglycerin
American Heart Journal, 1966 Solomon Fisch
openalex +4 more sources